(0.06%) 5 472.39 points
(0.10%) 39 150 points
(0.38%) 17 785 points
(0.02%) $80.85
(-3.66%) $2.66
(-0.80%) $2 312.20
(0.16%) $28.92
(3.45%) $1 020.40
(0.26%) $0.936
(0.68%) $10.68
(0.42%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology...
Stats | |
---|---|
今日成交量 | 26 283 |
平均成交量 | 83 430 |
市值 | 134.00M |
EPS | $-0.250 ( Q1 | 2024-05-07 ) |
下一个收益日期 | ( $-0.260 ) 2024-08-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.18 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0560 (0.77%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-13 | Kaplan Matthew L. | Buy | 30 000 | Common Stock |
2024-06-13 | Hoberman Kenneth | Buy | 30 000 | Common Stock |
2024-06-13 | Oliviero James F Iii | Buy | 30 000 | Common Stock |
2024-05-14 | Bentsur Ron | Buy | 1 940 | Common Stock |
2024-05-10 | Bentsur Ron | Buy | 2 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 1 141 381 | Sell: 0 |
音量 相关性
Nuvectis Pharma, Inc. 相关性 - 货币/商品
Nuvectis Pharma, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-22.90M (0.00 %) |
EPS: | $-1.430 |
FY | 2023 |
营收: | $0 |
毛利润: | $-22.90M (0.00 %) |
EPS: | $-1.430 |
FY | 2022 |
营收: | $149 000 |
毛利润: | $-19.09M (-12 808.72 %) |
EPS: | $-1.480 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.091 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。